Search
04/02/2022
CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
Rioja-Blanco, E, Arroyo-Solera, I, Alamo, P, Casanova, I, Gallardo, A, Unzueta, U, Serna, N, Sanchez-Garcia, L, Quer, M, Villaverde, A, Vazquez, E, Leon, X, Alba-Castellon, L, Mangues, R. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2022; 41(1)DOI:10.1186/s13046-022-02267-8. PMID:35120582. IF:11.300(Q1/1D).
01/02/2022
Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
Cortes-Vicente, E, Alvarez-Velasco, R, Pla-Junca, F, Rojas-Garcia, R, Paradas, C, Sevilla, T, Casasnovas, C, Gomez-Caravaca, MT, Pardo, J, Ramos-Fransi, A, Pelayo-Negro, AL, Gutierrez-Gutierrez, G, Turon-Sans, J, de Munain, AL, Guerrero-Sola, A, Jerico, I, Martin, MA, Mendoza, MD, Moris, G, Velez-Gomez, B, Garcia-Sobrino, T, Pascual-Goni, E, Reyes-Leiva, D, Illa, I, Gallardo, E. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology. 2022; 9(2)DOI:10.1002/acn3.51492. PMID:35080153. IF:5.300(Q1/2D).
01/02/2022
Structure and Dynamics of Large-Scale Cognitive Networks in Huntington's Disease
Aracil-Bolanos, I, Martinez-Horta, S, Gonzalez-de-Echavarri, JM, Sampedro, F, Perez-Perez, J, Horta, A, Campolongo, A, Izquierdo, C, Gomez-Anson, B, Pagonabarraga, J, Kulisevsky, J. Structure and Dynamics of Large-Scale Cognitive Networks in Huntington's Disease. MOVEMENT DISORDERS. 2022; 37(2)DOI:10.1002/mds.28839. PMID:34752656. IF:8.600(Q1/1D).
01/02/2022
The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses
Amoretti, S, Rosa, AR, Mezquida, G, Cabrera, B, Ribeiro, M, Molina, M, Bioque, M, Lobo, A, Gonzalez-Pinto, A, Fraguas, D, Corripio, I, Vieta, E, de la Serna, E, Morro, L, Garriga, M, Torrent, C, Cuesta, MJ, Bernardo, M, PEPs Grp. The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. PSYCHOLOGICAL MEDICINE. 2022; 52(3)DOI:10.1017/S0033291720002226. PMID:32900395. IF:6.900(Q1/1D).
01/02/2022
Fluid markers of synapse degeneration in synucleinopathies
Gonzalez, AC, Belbin, O. Fluid markers of synapse degeneration in synucleinopathies. JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02467-8. PMID:35147800. IF:3.300(Q2/5D).
01/02/2022
Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
Delaby, C, Alcolea, D, Hirtz, C, Vialaret, J, Kindermans, J, Morichon, L, Fortea, J, Belbin, O, Gabelle, A, Blennow, K, Zetterberg, H, Lleo, A, Lehmann, S. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02474-9. PMID:35169889. IF:3.300(Q2/5D).
01/02/2022
The A beta 1-42/A beta 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A beta 1-42 alone
Delaby, C, Estelles, T, Zhu, NU, Arranz, J, Barroeta, I, Carmona-Iragui, M, Illan-Gala, I, Santos-Santos, MA, Altuna, M, Sala, I, Sanchez-Saudinos, MB, Videla, L, Valldeneu, S, Subirana, A, Tondo, M, Blanco-Vaca, F, Lehmann, S, Belbin, O, Blesa, R, Fortea, J, Lleo, A, Alcolea, D. The A beta 1-42/A beta 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A beta 1-42 alone. Alzheimers Research & Therapy. 2022; 14(1)DOI:10.1186/s13195-022-00967-z. PMID:35105351. IF:9.000(Q1/1D).
01/02/2022
Proteinopathies: molecular mechanisms and diagnostic perspectives (vol 129, pg 129, 2022)
Delaby, C, Lehmann, S. Proteinopathies: molecular mechanisms and diagnostic perspectives (vol 129, pg 129, 2022). JOURNAL OF NEURAL TRANSMISSION. 2022; 129(2)DOI:10.1007/s00702-022-02473-w. PMID:35175386. IF:3.300(Q2/5D).